Agenda

Date and TimeTitle
Oct 27, 2020 (Eastern)
1:02pm - 1:30pm
Keynote: The Changing Landscape of Oncology Therapeutics: Incorporating Genomic Profiling
Oct 27, 2020 (Eastern)
1:40pm - 2:27pm
From Single-Gene Tests to Large Multi-Gene Panels: Should Genomic Testing in Cancer Be “One Size Fits All”?

Most personalized medicine therapies are targeted to the product of a single gene. When there were relatively few such drugs, single-gene tests generally sufficed to guide therapeutic decision making, and many approved CDx still fall in this category.  Now, however, considerably more targeted therapies are available for use in various cancers, with additional ones in clinical testing. In response, NGS tests for cancer gene alterations are becoming available that encompass ever-larger panels of genes and have potential to guide patients toward both appropriate approved therapies and targeted drug candidates in development.  While these multi-gene panel tests are acknowledged to have great clinical potential, many payer coverage policies reflect the perception that they don’t yet deliver utility commensurate with their cost. This panel will discuss issues of approved vs. investigational uses, clinical utility, cost-effectiveness, value, and others as it considers how each type of genomic testing assay best fits into the cancer care ecosystem.

Oct 27, 2020 (Eastern)
2:40pm - 3:00pm
Precision 20 – Bringing the Promise of Precision Oncology to Life

Dr. Prasanth Reddy will discuss the evolution of cancer treatment and how advancements in our understanding of genomics has led to a tipping point in precision cancer care.

Oct 27, 2020 (Eastern)
3:00pm - 3:50pm
Early Detection of Cancer
Oct 27, 2020 (Eastern)
3:57pm - 4:24pm
The Technology of Precision Medicine: Opportunities & Challenges for the Integration of Genomic Data Into Clinical Workflows

The promise of precision medicine requires physicians to have actionable patient genomic information at the point of care. So why haven’t we been able to effectively do so yet? Join James Hamrick, MD, MPH, senior medical director at Flatiron Health, as he speaks to the challenges & opportunities of leveraging technology to enable precision medicine in clinical workflows.

Oct 28, 2020 (Eastern)
2:15pm - 2:50pm
Keynote – T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Framework for Cancer Immunotherapy Drug Development

An effective anti-tumor immune response is associated with infiltration by type I/II interferon transcripts as well as chemokines associated with T cell trafficking. T cell-inflamed gene expression captures this biology within the tumor microenvironment and is a clinical biomarker of immunotherapy treatment response.  Understanding mechanisms of resistance in both the T cell-inflamed and non-T cell-inflamed subsets of tumors will be critical in overcoming treatment failure and expanding the proportion of patients responding to current immunotherapies. Moreover, characterizing the T cell-inflamed tumor microenvironment can nominate novel combination treatment regimens to bring into clinical trials with the intent of converting non-T cell-inflamed tumors into T cell-inflamed tumors as a means to sensitize tumors to therapies dependent on T-cell killing.

Oct 28, 2020 (Eastern)
2:50pm - 3:09pm
Market Access Considerations for a Successful CDx Launch

Level of evidence burden and specific evidence needs may vary by Dx test, but there is no substitute for clinical evidence – irrespective of business model Leverage the existing evidence landscape (clinical and economic burden of illness) to define the assay value Comparative data is essential – either against Standard of Care or Competition Create a reimbursement and evidence roadmap that is integrated with all other commercial activities and available at the time of launch (e.g. coding, pricing, partnering, and guidelines)

• Level of evidence burden and specific evidence needs may vary by Dx test, but there is no substitute for clinical evidence – irrespective of business model
• Leverage the existing evidence landscape (clinical and economic burden of illness) to define the assay value
• Comparative data is essential – either against Standard of Care or Competition
• Create a reimbursement and evidence roadmap that is integrated with all other commercial activities and available at the time of launch (e.g. coding, pricing, partnering, and guidelines)

Oct 28, 2020 (Eastern)
3:18pm - 3:58pm
Keynote: Revolutionizing Cancer Treatment and Detection with Biomarkers

Immuno-oncology based treatments have shown tremendous promise for improving how we treat cancers. In fact, studies have shown that immunotherapy drugs can extend the lives of advanced cancer patients not by months, but by years. However, creating safe and effective drugs to combat the disease has been challenged by a lack of reliable methods to determine whether immunotherapies are having the desired effect. In this session, Kevin Hrusovsky, Quanterix President and CEO and founder Powering Precision Health, will discuss how new advances in highly sensitive multiplex assays are enabling researchers to identify and quantify multiple oncology biomarkers simultaneously to more quickly see the effects of certain drugs on individual cancer patients, even at the earliest stages of the disease. By measuring concentrations of key circulating cytokines and immunological biomarkers across all stages of disease progression, including normal healthy baseline levels, researchers can determine whether an immunotherapy or other cancer treatment is working, optimize dosing and minimize toxicity to avoid severe side effects. Kevin will detail real-world examples of this as informed by researchers across the global Powering Precision Health ecosystem. He will also explore the promise of true precision health in oncology and his vision for eliminating invasive mammograms and biopsies in favor of a routine blood test, making proactive cancer care as simple as a cholesterol screen.